Session I: Imaging Theragnostics

Chair: Jeffrey Evelhoch, Amgen

The promises and realities of imaging as a biomarker to accelerate drug development
Timothy McCarthy, Pfizer

Antibodies: The ideal diagtherapeutic
Andrew Raubitschek, City of Hope

Session 3: Quantitative Image Analysis

Chair: Jeffrey Duerk, Case Western Reserve University

Algorithms for quantitative assessment of pediatric brain MRI
Simon Warfield, Children’s Hospital Boston

Cryo-imaging of whole mice & counting single fluorescently labeled cells
David Wilson, Case Western Reserve University

Session 5: Horizons of Hyperpolarization

Chair: Joseph Ackerman, Washington University

Recent advances with PHIP
Elena Vinogradov, Beth Israel Deaconess Medical Center

Diffusion-MRI of lungs and emphysema with hyperpolarized Helium-3
Mark Conradi, Washington University

Can hyperpolarized carbon be used for quantitative metabolic flux measurements?
Matthew Merritt, University of Texas Southwestern

Hyperpolarized C-13 metabolic probes for the detection& characterization of prostate cancer prior to and after therapy
John Kurhanewicz, UC San Francisco

Session 7: Activatable Agents

Chair: Tom Meade, Northwestern University

PARACEST MRI contrast agents that detect enzyme activities
Marty Pagel, Case Western Reserve University

MRI-guided cancer therapy: Gadolinium-encapsulated carbon nanostructures for theragnostics
Lon Wilson, Rice University

Session 9: Imaging Hypoxia

Chair: Robert Gillies, University of Arizona

Quantitatve assessment of tumor hypoxia by electron paramagnetic resonance
Murali C. Krishna, National Institutes of Health

Testing the clinical implications of hypoxia imaging
Kenneth Krohn, University of Washington